Adobe
By Meghana Keshavan
April 30, 2026
Biotech Correspondent
Meghana Keshavan
Five-way obesity drug is super effective — in mice
A 'quintuple agonist,' Alector halts it Alzheimer's trial, and more biotech news from The Readout
331 words~2 min read
Related reading
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new…
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in…
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out…
Lilly's retatrutide has been offered to a single person via 'compassionate use'…
The "triple-G" weight loss drug, Pfizer's lung cancer trial results, and more biotech news from The Readout
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’…
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And…